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Abstract:  
Shattell and Keltner present a case for atypical antipsychotics in bipolar disorder. Moreover, they 
review current research that supports the effectiveness of several antipsychotics, including 
olanzapine, quetiapine, and ziprasidone, in treating such disorder. They assert that managing 
symptoms through psychotropic medications can help people with mental disabilities better 
manage their lives. 
 
Article: 
Nothing is more addictive than the high of a manic euphoria. 
-Margo Orum, 1996 
 
Bipolar disorder has risen almost to the level of diagnosis du jour. Sheer numbers will not allow 
it to eclipse the attention directed at social anxiety disorder, depression, or attention deficit 
hyperactivity disorder, but a quick review of mailings received in the last 6 months will reveal a 
tremendous surge of interest in this disorder. Major conferences, drug company symposia, and 
online continuing education programs have increasingly focused on this mental health problem. 
 
Scenario 
Demographics A young man (Bob, age 30) and a young woman (Mary, age 26) betrothed, with 
wedding date planned for the near future. 
 
Background Both college educated with particularly promising careers. 
 
The Setting Mary flies into a rage and breaks off the engagement when Bob asks her if she'll let 
the pets out. Mary leaves for 3 weeks, then returns the day before a relative's funeral. Bob attends 
with her, and she introduces him as her fiancé. 
 
The Crisis After the funeral she tells Bob: "I got married to my old boyfriend while I was gone. 
It was a mistake. I went to see my doctor. he thinks I have bipolar disorder." 
 
The incidence of bipolar varies considerably among studies-from 0.4% to 1.6%, with ranges to 
7% suggested when the full spectrum of bipolar disorders is included (American Psychiatric 
Association, 2000; Ghaemi, 2001; Kessler, Stang, Wittchen, Stein, & Walters, 1999). Typically, 
a first-time diagnosis occurs around 20 years of age but, as in the scenario above, 26 is within the 
normal limits. Even though diagnosis may not be made until the third decade, prodromal 
behaviors during the teenage years often give hints of future morbidity. Treatment is often 
lifelong, because the disorder tends to be lifelong. It is a significant problem and seems to figure 
more prominently in society's thinking today than it was just 10 or 15 years ago. 
 
As the scenario above suggests, a manic episode can wreak havoc in the life of the individual and 
those close to that person. Since such scenarios are not uncommon, the search for effective 
treatment continues to be a high priority for clinicians and patients. While lithium is still the gold 
standard, about 50% of patients do not improve substantially on this medication (Scares, 
Mallinger, & Gershon, 1997). Likewise, valproates (i.e., divalproex, sodium valproate, valproic 
acid) and carbamazepine are effective pharmacologie interventions for many, but not for all, 
bipolar patients. This reality has triggered extensive efforts to develop and/or find suitable 
adjunctive or monotherapies for the many individuals who are unsatisfactorily treated with 
lithium and anticonvulsants. A drug category of major interest, and most often the focus of the 
aforementioned conferences, symposia, etc., is the atypical antipsychotic drug (or medication) 
group. 
 
Until recently, antipsychotics were not considered first-line agents for treating bipolar disorder. 
Algorithms developed to assist clinicians recommended atypical antipsychotics when lithium and 
the anticonvulsants were ineffective, and typically only then in an adjunctive role. The Texas 
Medication Algorithm Project for Mania supports the use of the atypical olanzapine, an 
alternative to lithium or divalproex, for acute mania (Suppes et al., 2003). 
 
Before reviewing individual agents, it should be noted that a commonly used tool for measuring 
mania is the Young Mania Rating Scale (YMRS) (Young, Biggs, Ziegler, & Meyer, 1978). The 
scale has 11 items (Table 1), with a maximum score of 60. Table 2 expands one of the items of 
the YMRS for those unfamiliar with the scale. A typical minimum score for inclusion in a 
clinical trial is 20. Improvement is often defined as a decrease in symptoms by 50%; however, 
for some studies, remission may be the objective and defined as an YMRS of <15. It is important 
to notice how success is being measured on a particular study. 
 
Olanzapine 
Olanzapine (Zyprexa) is approved for bipolar disorder; companies producing other drugs are also 
pursuing this indication. Olanzapine has been shown to be more effective than placebo 
(Chengappa et al., 2003; Sanger et al., 2003; Tohen et al., 1999, 2002), superior to haloperidol 
(Shi et al., 2002; Tollefson et al., 1997), and as effective as lithium or divalproex (Berk, Ichim, & 
Brook, 1999; Revicki et al, 2003; Sanger et al, 2001; Tohen et al., 2003; Zajecka et al., 2002) in 
treating bipolar disorder (Keltner, 2003). In head-to-head measurements with divalproex, 
olanzapine caused a 50% decline in YMRS scores in a 12-week study, while divalproex did not 
(Tohen et al., 2002). Although differences in outcome were not statistically significant, this study 
indicated olanzapine produces a slightly better effect than divalproex. Further, the olanzapine-
treated group responded more rapidly, a potentially important effect (Stimmel, 2003).  
 
Somnolence, weight gain, and rhinitis developed in 45%, ~25%, and ~15% of patients, 
respectively (Tohen et al., 2002). Typical dosage for olanzapine was between 15 and 45 mg/day. 
Dennehy, Doyle, and Suppes (2003) found olanzapine to be highly effective in treating mania 
and less effective in treating depression in a sample of outpatients diagnosed with bipolar 
disorder. 
 
Anecdotal reports of olanzapine causing manic-type symptoms were not supported in a study by 
Baker, Milton, Stauffer, Gelenberg, & Tohen (2003). These authors suggest that changes in 
manic behavior are the result of the natural variations in bipolar disorder, not the result of 
olanzapine (or other atypical antipsychotic drug). Because of these and other studies, olanzapine 
has received Food and Drug Administration (FDA) approval as an antimanic drug. 
 
Quetiapine 
Quetiapine (Seroquel) has recently gained FDA approval for bipolar disorder. It has been 
associated with low to moderate weight gain, few extrapyramidal effects, and little if any 
elevation in prolactin (McConville et al., 2003). The latter effect is probably related to 
improvements in sex life when patients are switched to quetiapine (Byerly et al., 2002). Major 
adverse responses include relatively high levels of somnolence, dizziness, and postural 
hypotension. Zarate, Rothschild, Fletcher, Madris, and Zapatel (2000) noted improvement in 
patients with psychotic mood disorders prescribed quetiapine. Ereshefsky (2003) reports a study 
presented at the 2003 American Psychiatric Association meeting in which quetiapine was found 
comparable to lithium and haloperidol for bipolar disorder treatment. This study found 
quetiapine effective not only at 3 weeks (a typical study length) but also at 12 weeks, suggesting 
a sustained effect. When data were pooled to align quetiapine against placebo, significance was 
even more pronounced (Keltner, 2003). McConville et al. studied the long-term use (88 weeks) 
of quetiapine in adolescents with bipolar disorder and schizoaffective disorder and found that it 
was highly effective, with no extrapyramidal side-effects and minimal weight gain. This is the 
first known long-term study of its use with an adolescent population and holds promise for 
further study and treatment. 
 
Risperidone 
Risperidone (Risperdal) has proved comparable to haloperidol and lithium in reducing manic 
symptoms (Segal, Berk, & Brook, 1998) and superior to placebo as an adjunctive to lithium 
(Keck et al., 2000; Sachs, Printz, Kahn, Carpenter, & Docherty, 2000). It can be given on a once 
per day basis. Weight gain has been recorded as moderate in scope, but extrapyramidal side 
effects have been more pronounced. In a risperidone vs. placebo study, risperidone was found to 
have a rapid effect and a sustained advantage over the course of the study (Hirschfeld, 2003). 
Risperidone is typically dosed at < or =6 mg/day. Risperidone is not FDA approved for bipolar 
disorder. 
 
Ziprasidone 
Ziprasidone (Geodon) has been compared favorably to placebo for the treatment of mania (Keck 
et al., 2003). In this study, separation of effects were observed after 2 days, indicating a rapid 
onset, and ziprasidone continued to enjoy significantly better decline in YMRS scores than 
placebo after 2 weeks. This study and its findings are somewhat diminished by the large number 
of dropouts (46% for ziprasidone, 56% in the placebo group). Ziprasidone study patients suffered 
a greater level of extrapyramidal effects, dizziness, and somnolence than the placebo group; 
however, neither weight gain nor significant changes in vital signs occurred. QT interval 
elongation was not observed. Patients were titrated rapidly to 60-80 mg/day. Ziprasidone is not 
FDA approved for bipolar disorder. 
 
Aripiprazole 
Aripiprazole (Abilify), the newest antipsychotic drug, also has been studied for efficacy in 
bipolar disorder. Aripiprazole has the unique property of providing partial agonism at dopamine 
receptors (Keltner & Johnson, 2002) and is promoted as a dopamine system stabilizer. 
Ereshefsky (2003) reports a study that compared aripiprazole (n = 123) to placebo (n = 122) at a 
dose of 30 mg per day. A significant separation of effect developed within four days and was 
sustained over the study. This research indicates, and anecdotal reports support, a relatively high 
occurrence of nausea and akathisia with this drug. 
 
Clozapine 
Clozapine (Clozaril) is the gold standard for antipsychotic treatment and may be one of the best 
drugs for hard-to-treat cases of bipolar disorder as well. Clozapine carries a small risk for 
agranulocytosis and because of this, is a second-tier choice for bipolar disorder. Nonetheless, 
clozapine has proved effective in trials. Green et al. (2000) compared clozapine to treatment-as-
usual (defined as the treatment to which the patient with chronic bipolar disorder had been 
exposed) for patients who were refractory to treatment (defined as no improvement after 6 weeks 
of treatment with chlorpromazine [Thorazine] or lithium). A significantly higher number of 
patients who switched to clozapine did improve. As noted earlier, it is important to understand 
how improvement is operationally defined. In this study, improvement was defined as a decrease 
in YMRS scores of 30%. 
 
Ciapparelli et al. (2003) studied the long-term effect of clozapine on patients with bipolar 
disorder, schizoaffective disorder, and schizophrenia. The authors found that all groups improved 
significantly, measured with the Brief Psychiatric Rating Scale (BPRS) and Clinical Global 
Impressions-Severity of Illness scale. The bipolar group improved more rapidly than the other 
two groups; the bipolar groups cut in half its baseline data in just 3 months, the schizoaffective 
group in 6 months, and the schizophrenia group in 24 months. Both of these studies indicate that 
clozapine may be an important agent in hard-to-treat cases of bipolar disorder. 
 
Summary 
As the opening scenario illustrates about Mary and Bob, bipolar disorder can be devastating to 
individuals and families. Managing symptoms through psychotropic medications can help people 
with mental illness better manage their lives. Our brief review of the current research supports 
the effectiveness of atypical antipsychotic medications and, therefore, supports their use in 
treating bipolar disorder. 
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